Transparency audit
What still needs work.
This page intentionally exposes gaps. A serious YMYL project should show what is known, what is missing, and what cannot be claimed yet.
24 records
Missing Korean source support
- Tunlametinib / HL-085
- Nivolumab + relatlimab
- BRAF + MEK inhibitor combinations
- Lifileucel tumor-infiltrating lymphocyte therapy
- Chemotherapy in melanoma
- T-VEC / talimogene laherparepvec
- Vemurafenib + cobimetinib
- Imatinib / KIT-context melanoma
- Regorafenib / KIT-context research lead
- Belvarafenib + cobimetinib ± nivolumab
- Trametinib + hydroxychloroquine
- Tunlametinib + nivolumab unresolved lead
- Light-based local therapies in melanoma
- Oxygen therapy / hyperbaric oxygen in melanoma context
- Heat therapy / hyperthermia and regional melanoma therapy
- Leukemia subtype and testing map
- Acute myeloid leukemia source map
- Acute lymphoblastic leukemia source map
- Chronic lymphocytic leukemia source map
- Chronic myeloid leukemia / BCR-ABL source map
- CML controlled with regular TKI medicine
- CML treatment-free remission discussion
- Allogeneic stem cell transplant: curative intent with major risks
- Clinical trial search strategy
2 records
Unresolved leads
- Regorafenib / KIT-context research lead
- Tunlametinib + nivolumab unresolved lead
20 records
Missing related trial IDs
- PD-1 inhibitors: nivolumab and pembrolizumab
- Nivolumab + relatlimab
- BRAF + MEK inhibitor combinations
- Lifileucel tumor-infiltrating lymphocyte therapy
- Pembrolizumab
- Nivolumab + ipilimumab
- Ipilimumab
- T-VEC / talimogene laherparepvec
- Vemurafenib + cobimetinib
- Imatinib / KIT-context melanoma
- Regorafenib / KIT-context research lead
- Light-based local therapies in melanoma
- Oxygen therapy / hyperbaric oxygen in melanoma context
- Heat therapy / hyperthermia and regional melanoma therapy
- Leukemia subtype and testing map
- Acute myeloid leukemia source map
- Acute lymphoblastic leukemia source map
- Chronic lymphocytic leukemia source map
- Chronic myeloid leukemia / BCR-ABL source map
- Allogeneic stem cell transplant: curative intent with major risks
0 records
Company-only source risk
No current patient-facing record is allowed to rely only on a company source.
Condition coverage
Options mapped for every condition; melanoma also goes deeper.
Every condition page has sourced options by country. Melanoma additionally carries stage and mutation pages and cohort forum links — its in-depth tier.
| Condition | Status | Current support | Next needed work |
|---|---|---|---|
| Melanoma | In-depth guide | Options by country + stage and mutation pages | Keep extending melanoma's stage and mutation pages; every other condition already has a sourced options-by-country map. |
| Lung cancer | Options mapped | Options by country and visit-prep questions | Extend subtype and biomarker detail as new sources pass verification. |
| Breast cancer | Options mapped | Options by country and visit-prep questions | Extend subtype detail as receptor-status sources pass verification. |
| Colorectal cancer | Options mapped | Options by country and visit-prep questions | Split colon and rectal tracks further as source-backed biomarker records expand. |
| Leukemia | Options mapped | Options by country and visit-prep questions | Extend subtype-specific AML, ALL, CLL, and CML detail as research records pass verification. |
| Leukemia / lymphoma | Options mapped | Options by country and visit-prep questions | Use /cancers/leukemia for leukemia; lymphoma detail continues to expand. |
| Pediatric solid tumors | Options mapped | Options by country and visit-prep questions | Extend the pediatric source map and reviewer pipeline as new options pass verification. |
| Adrenocortical carcinoma | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Amyotrophic lateral sclerosis (ALS) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Anal cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Appendiceal cancer / pseudomyxoma peritonei | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Atypical hemolytic uremic syndrome (aHUS) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Beta-thalassemia | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Biliary tract cancer / cholangiocarcinoma | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| CNS glioma (brain tumor) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Cancer of unknown primary (CUP) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Cervical cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Cystic fibrosis | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Duchenne muscular dystrophy (DMD) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Endometrial cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Esophageal cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Fabry disease | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Gastric / gastro-oesophageal junction cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Gaucher disease | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Generalized myasthenia gravis (gMG) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Gestational trophoblastic disease / neoplasia | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Head and neck cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Hemophilia A / B | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Hepatocellular carcinoma (liver cancer) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Hereditary angioedema (HAE) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Huntington's disease | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Idiopathic pulmonary fibrosis (IPF) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Inherited retinal dystrophy (RPE65) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Langerhans cell histiocytosis | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Merkel cell carcinoma | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Mesothelioma | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Mucopolysaccharidosis (MPS) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| NUT carcinoma | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Neuroendocrine tumor (NET) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Neurofibromatosis (NF1 / NF2) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Neuromyelitis optica spectrum disorder (NMOSD) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Non-melanoma skin cancer (BCC / cSCC) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Ovarian cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Pancreatic cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Paroxysmal nocturnal hemoglobinuria (PNH) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Penile cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Phenylketonuria (PKU) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Pompe disease | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Prostate cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Pulmonary arterial hypertension (PAH) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Renal cell carcinoma (kidney cancer) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Sarcoma (incl. GIST) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Sickle cell disease | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Spinal muscular atrophy (SMA) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Testicular germ cell cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Thymic carcinoma / thymoma | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Thyroid cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Transthyretin (ATTR) amyloidosis | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Tuberous sclerosis complex (TSC) | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Tumor-agnostic / NTRK fusion-positive solid tumors | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Urothelial / bladder cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Uveal melanoma | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
| Vulvar / vaginal cancer | Options mapped | Options by country and visit-prep questions | Extend coverage for this condition as new sources pass verification. |
Open research gaps
closed-not-found
Is there a melanoma trial or publication for the exact tunlametinib / HL-085 plus nivolumab combination?
ClinicalTrials.gov searches for tunlametinib/HL-085 plus nivolumab melanoma returned no exact record in this pass. Related records support tunlametinib monotherapy after prior immunotherapy and other MEK/RAF-plus-PD-1 concepts, but those should not be merged with the exact remembered combination.
open
Which melanoma drugs are reimbursed or practically available in Korea by mutation and line of therapy?
KCIC provides patient-facing melanoma, immunotherapy, and targeted-therapy background. A drug-by-drug Korea reimbursement map still needs Korean regulatory/reimbursement source work.
open
Which melanoma drugs are approved and practically accessible in Japan by mutation and line of therapy?
Japan NCC/ganjoho and PMDA are source buckets. Nivolumab PMDA material was identified, but full drug-by-drug mapping remains unfinished.
1 condition
In-depth guide
- Melanoma
62 conditions
Options mapped
- Lung cancer
- Breast cancer
- Colorectal cancer
- Leukemia
- Leukemia / lymphoma
- Pediatric solid tumors
- Adrenocortical carcinoma
- Amyotrophic lateral sclerosis (ALS)
- Anal cancer
- Appendiceal cancer / pseudomyxoma peritonei
- Atypical hemolytic uremic syndrome (aHUS)
- Beta-thalassemia
- Biliary tract cancer / cholangiocarcinoma
- CNS glioma (brain tumor)
- Cancer of unknown primary (CUP)
- Cervical cancer
- Cystic fibrosis
- Duchenne muscular dystrophy (DMD)
- Endometrial cancer
- Esophageal cancer
- Fabry disease
- Gastric / gastro-oesophageal junction cancer
- Gaucher disease
- Generalized myasthenia gravis (gMG)
- Gestational trophoblastic disease / neoplasia
- Head and neck cancer
- Hemophilia A / B
- Hepatocellular carcinoma (liver cancer)
- Hereditary angioedema (HAE)
- Huntington's disease
- Idiopathic pulmonary fibrosis (IPF)
- Inherited retinal dystrophy (RPE65)
- Langerhans cell histiocytosis
- Merkel cell carcinoma
- Mesothelioma
- Mucopolysaccharidosis (MPS)
- NUT carcinoma
- Neuroendocrine tumor (NET)
- Neurofibromatosis (NF1 / NF2)
- Neuromyelitis optica spectrum disorder (NMOSD)
- Non-melanoma skin cancer (BCC / cSCC)
- Ovarian cancer
- Pancreatic cancer
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Penile cancer
- Phenylketonuria (PKU)
- Pompe disease
- Prostate cancer
- Pulmonary arterial hypertension (PAH)
- Renal cell carcinoma (kidney cancer)
- Sarcoma (incl. GIST)
- Sickle cell disease
- Spinal muscular atrophy (SMA)
- Testicular germ cell cancer
- Thymic carcinoma / thymoma
- Thyroid cancer
- Transthyretin (ATTR) amyloidosis
- Tuberous sclerosis complex (TSC)
- Tumor-agnostic / NTRK fusion-positive solid tumors
- Urothelial / bladder cancer
- Uveal melanoma
- Vulvar / vaginal cancer